Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
作者： Timothy W. Jacobs , Allen M. Gown , Hadi Yaziji , Melissa J. Barnes , Stuart J. Schnitt
DOI: 10.1200/JCO.1999.17.7.1974
关键词:
摘要: PURPOSE: To compare fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) the determination of HER-2/neu status breast cancers. MATERIALS AND METHODS: FISH IHC for were performed on formalin-fixed paraffin sections 100 consecutive invasive was at Beth Israel Deaconess Medical Center, Boston, MA, using Oncor/Ventana INFORM kit (Ventana Systems, Tucson, AZ; formerly sold by Oncor, Inc, Gaithersburg, MD) a laboratory certified as proficient this procedure. PhenoPath Laboratories, Seattle, WA, polyclonal antibody to protein. analyzed blinded fashion, results then compared. Procedure interpretation times reagent costs also RESULTS: amplified 26% cases, 23% HER-2/neu–positive IHC. FISHand both assessable 90 cases. Concordance between results...
sci-hub.se 参考文章(71)
B. Tetu, V. Plante, J. Brisson, P. Bernard, p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Modern Pathology. ,vol. 11, pp. 823- 830 ,(1998)
G Y Wong, M P Osborne, R K Tiwari, C Cordon-Cardo, P I Borgen, HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Research. ,vol. 12, pp. 419- 425 ,(1992)
Frederick C. Koerner, Dennis L. Panicali, Steven J. Skates, Ann D. Thor, Sara J. McKenzie, Susan M. Edgerton, Paula J. Marks, Howard J. Fingert, William C. Wood, Laurent H. Schwartz, Samuel Yin, Analysis of c-erbB-2 Expression in Breast Carcinomas with Clinical Follow-up Cancer Research. ,vol. 49, pp. 7147- 7152 ,(1989)
Gabriel Hortobagyi, Jae Y. Ro, Mark Blick, Debra Frye, Herbert Fritsche, Jungsil Ro, Adel K El-Naggar, Giuseooe Fraschini, c-erbB-2 Amplification in Node-negative Human Breast Cancer Cancer Research. ,vol. 49, pp. 6941- 6944 ,(1989)
W J Gullick, P Kelly, Sainsbury, C Wright, A L Harris, B Angus, J Cairns, S Nicholson, C H Horne, Expression of c-erbB-2 Oncoprotein: A Prognostic Indicator in Human Breast Cancer Cancer Research. ,vol. 49, pp. 2087- 2090 ,(1989)
Godolphin W, Pauletti G, Press Mf, Slamon Dj, Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. ,vol. 13, pp. 63- 72 ,(1996)
G Gasparini, W J Gullick, P Bevilacqua, J R Sainsbury, S Meli, P Boracchi, A Testolin, G La Malfa, F Pozza, Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. Journal of Clinical Oncology. ,vol. 10, pp. 686- 695 ,(1992) , 10.1200/JCO.1992.10.5.686
B A Gusterson, R D Gelber, A Goldhirsch, K N Price, J Säve-Söderborgh, R Anbazhagan, J Styles, C M Rudenstam, R Golouh, R Reed, Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology. ,vol. 10, pp. 1049- 1056 ,(1992) , 10.1200/JCO.1992.10.7.1049
William L. McGuire, Gary M. Clark, Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Research. ,vol. 51, pp. 944- 948 ,(1991)
S Paik, R Hazan, E R Fisher, R E Sass, B Fisher, C Redmond, J Schlessinger, M E Lippman, C R King, Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology. ,vol. 8, pp. 103- 112 ,(1990) , 10.1200/JCO.1990.8.1.103